Profile

Regeneron (NASDAQ: REGN) is a leading biotechnology company dedicated to inventing, developing, and commercializing life-transforming medicines for individuals with serious diseases. Founded and led by physician-scientists, the company has consistently translated scientific discoveries into medical advancements, resulting in numerous approved treatments and a robust pipeline of product candidates, many of which originated in its own laboratories. Regeneron’s medicines and pipeline address a wide range of conditions, including eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic disorders, neurological diseases, hematologic conditions, infectious diseases, and rare diseases.

The company is at the forefront of scientific innovation, accelerating drug development through proprietary technologies such as VelociSuite®, which produces optimized fully human antibodies and novel bispecific antibody classes. Leveraging data-driven insights from the Regeneron Genetics Center® and advancing genetic medicine platforms, Regeneron is identifying groundbreaking targets and complementary approaches to potentially treat or cure diseases, shaping the future of medicine.

Visit www.regeneron.com

Key Products

EYLEA® (aflibercept) & EYLEA® HD (aflibercept) Injection 8mg

EYLEA HD is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

EYLEA is a prescription medicine approved for the treatment of patients with Wet Age-Related Macular Degeneration (AMD), Macular Edema following Retinal Vein Occlusion (RVO), Diabetic Macular Edema (DME), and Diabetic Retinopathy (DR).

Visit www.eyleahd.com to learn more, including important safety information.

Dupixent® (dupilumab)

DUPIXENT is a prescription medicine used to treat eczema (atopic dermatitis), certain types of asthma, chronic rhinosinusitis with nasal polyps (CRSwNP), eosinophilic esophagitis (EoE), and prurigo nodularis (PN).

Visit www.dupixent.com to learn more, including important safety information.

Libtayo® (cemiplimab-rwlc)

LIBTAYO is a prescription medicine used to help treat certain types of cancer (cutaneous squamous cell carcinoma, basal cell carcinoma, and non-small cell lung cancer) working with your immune system.

Visit www.libtayo.com to learn more, including important safety information.

Key Executives

Leonard S. Schleifer, M.D., Ph.D., founded the Company in 1988 and has been a director and its President and Chief Executive Officer since its inception. Dr. Schleifer has served as co-Chair of the Board since 2023 and previously served as Chair of the Board from 1990 through 1994. Dr. Schleifer, together with Regeneron’s founding scientist, Dr. Yancopoulos, built and has managed the Company over the past 36+ years. Dr. Schleifer received his M.D. and Ph.D. in Pharmacology from the University of Virginia. Dr. Schleifer is a licensed physician and is certified in Neurology by the American Board of Psychiatry and Neurology.

George D. Yancopoulos, M.D., Ph.D., joined Dr. Schleifer in 1989 as founding scientist of the Company, and together they built and have managed the Company since then. Dr. Yancopoulos is currently President and Chief Scientific Officer, and has served as a director since 2001 and as co-Chair of the Board since 2023. He received his M.D. and Ph.D. from Columbia University. Dr. Yancopoulos was the 11th most highly cited scientist in the world in the 1990s, and in 2004 he was elected to be a member of the National Academy of Sciences. Dr. Yancopoulos, together with key members of his team, is a principal inventor and/or developer of the 13 approved or authorized treatments the Company has developed, as well as its foundational technologies,including the TRAP technology, VelociGene®, and VelocImmune®.

Christopher Fenimore has been Senior Vice President, Finance and Chief Financial Officer since February 2024. He previously served as Senior Vice President, Controller from January 2021 to February 2024, as Vice President, Controller from March 2017 to December 2020, as Vice President, Deputy Controller from January 2017 to March 2017, and as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance for a biotechnology start-up and worked in other healthcare industry-focused venture capital and investment banking roles. Mr. Fenimore started his career as an auditor at KPMG and is a Certified Public Accountant in the State of New York. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University.

Joseph J. LaRosa has been Executive Vice President, General Counsel and Secretary since January 2019. From September 2011 to December 2018, he served as Senior Vice President, General Counsel and Secretary. Before joining Regeneron, Mr. LaRosa was Senior Vice President, General Counsel, and Secretary at Nycomed US Inc. Mr. LaRosa’s prior experience includes working in a number of senior legal positions at Schering-Plough Corporation from 1993 to 2009, where he was a corporate officer and served most recently as Vice President, Legal Affairs, and a member of the Operations Management Team. Mr. LaRosa received his J.D. from New York University School of Law.

Marion McCourt has been Executive Vice President, Commercial since January 2021. She previously served as Senior Vice President, Commercial from February 2018 to December 2020. From April 2017 until joining the Company, Ms. McCourt served as the Principal Operating Officer and the Chief Operating Officer and President of Axovant Sciences, Inc. Ms. McCourt previously served as chief operating officer of Medivation, Inc. from February 2016 until its acquisition by Pfizer Inc. in September 2016. Previously, Ms. McCourt worked at Amgen Inc., where she most recently served as a Vice President in U.S. Commercial Operations from February 2014 to January 2016. From May 2013 to January 2014, Ms. McCourt served as Vice President and General Manager at Amgen where she was responsible for the bone health and primary care business unit. From 2012 to 2013, she was Chief Operating Officer for AstraZeneca U.S., a division of AstraZeneca plc. Her responsibilities included oversight and leadership of all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations, and corporate affairs. During her 12-year tenure at AstraZeneca, Ms. McCourt was President and Chief Executive Officer of AstraZeneca Canada Inc. from 2011 to 2012 and also held various other roles at AstraZeneca Pharmaceuticals LP, a subsidiary of AstraZeneca plc. Ms. McCourt received her B.S. in Biology from Lafayette College.

Andrew J. Murphy, Ph.D., has been Executive Vice President, Research since January 2019. He previously served as Senior Vice President, Research, Regeneron Laboratories from January 2013 to December 2018, as Vice President, Target Discovery from May 2005 to December 2012, as Vice President, Gene Discovery and Bioinformatics from January 2001 to May 2005, and as Director of Genomics and Bioinformatics from May 1999 to December 2000. Dr. Murphy is a co-inventor of several of the Company’s key technologies, including VelociGene® and VelocImmune®, and continues to lead several technology centers and therapeutic focus areas. He received his B.S. in Molecular Biology at the University of Wisconsin, and his Ph.D. in Human Genetics from Columbia University, College of Physicians and Surgeons.

Neil Stahl, Ph.D., has been Executive Vice President, Research and Development since January 2015. He previously served as Senior Vice President, Research and Development Sciences from January 2007 to December 2014, as Senior Vice President, Preclinical Development and Biomolecular Sciences from December 2000 to December 2007, and as Vice President, Preclinical Development and Biomolecular Sciences from January 2000 to December 2000. He joined the Company in 1991. Before becoming Vice President, Biomolecular Sciences in 1997, Dr. Stahl was Director, Cytokines and Signal Transduction. Dr. Stahl received his Ph.D. in Biochemistry from Brandeis University.

Daniel P. Van Plew has been Executive Vice President and General Manager, Industrial Operations and Product Supply since January 2016. From April 2008 to December 2015, Mr. Van Plew served as Senior Vice President and General Manager, Industrial Operations and Product Supply. Prior to that date, he served as Vice President and General Manager, Industrial Operations and Product Supply since joining the Company in 2007. From 2006 until 2007, Mr. Van Plew served as Executive Vice President, R&D and Technical Operations of Crucell Holland B.V., a global biopharmaceutical company. Between 2004 and 2006, Mr. Van Plew held positions of increasing responsibility at Chiron Biopharmaceuticals, part of Chiron Corporation, a biotechnology company, most recently as Senior Director, Vacaville Operations. From 1998 until 2004, Mr. Van Plew held various managerial positions in the health and life sciences practice at Accenture, Ltd., a management consulting business. Mr. Van Plew received his M.S. in Chemistry from The Pennsylvania State University and his M.B.A. from Michigan State University.

Customer Insights

Regeneron is consistently ranked as a top company. Select 2023 – 2024 honors include:

• TIME: World’s Most Sustainable Companies


• US News & World Report: Best Companies to Work for


• IDEA Pharma: Top 10 Pharmaceutical Innovation/Invention Index


• Disability: IN & American Association of People with


• Disabilities: Best Place to Work for Disability Inclusion


• Newsweek: America’s Greatest Workplaces for Diversity


• Newsweek: America’s Most Responsible Companies


• Biospace: Best Place to Work


• Science: Top Employers


• S&P Global: Dow Jones Sustainability World & North America Index
  
  Human Rights Campaign Foundation: Corporate Equality Index


• Fast Company: Best Workplaces for Innovators


• Forbes: America’s Best Employers for Women


• Newsweek: America’s Greenest Companies


• Civic 50: Most Community-Minded Companies in the Nation


• Glassdoor: Best Places to Work

Investors

Regeneron is a publicly listed company with a market capitalization of nearly $130 billion. Its unwavering commitment to patients, groundbreaking research and development, and successful commercial execution have driven substantial shareholder value. Over a 10-year period (2014–2024), the company delivered a total shareholder return of 219%, outperforming both the broader market and the biotechnology industry. In early 2024, Regeneron achieved a significant milestone by surpassing a $100 billion market capitalization, positioning itself as one of the few biotechnology companies to reach this valuation. This achievement underscores Regeneron’s ability to fulfill its mission and highlights its strong future prospects.

Competitors

• Vertex


• Gilead


• Biogen


• Amgen


• BMS

Corporate Responsibility

Regeneron’s mission is to harness the power of science to consistently deliver life-changing medicines to patients. The company is dedicated to operating responsibly, engaging stakeholders transparently, and addressing its impacts openly. Guided by the principle of “Doing Well by Doing Good,” Regeneron integrates corporate responsibility into its core operations and discloses detailed information about significant responsibility matters through its annual responsibility reports. The company’s 2025 responsibility goals focus on three key areas, addressing the environmental and social issues most relevant to its business and stakeholders.

In 2023, Regeneron achieved notable progress toward many of these goals. Highlights from each focus area are summarized in its 2023 Responsibility Report, which provides a comprehensive overview of these achievements.